US 11,957,669 B2
Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
Joon Ho Choi, Yongin-si (KR); Won Kyung Cho, Yongin-si (KR); Kwang-Hyun Shin, Yongin-si (KR); Byoung Young Woo, Yongin-si (KR); Ki-Wha Lee, Yongin-si (KR); Min-Soo Kim, Busan (KR); Jong Hwa Roh, Yongin-si (KR); Mi Young Park, Yongin-si (KR); Young-Ho Park, Yongin-si (KR); Eun Sil Park, Yongin-si (KR); and Jae Hong Park, Yongin-si (KR)
Assigned to AMOREPACIFIC CORPORATION, Seoul (KR)
Appl. No. 16/638,038
Filed by AMOREPACIFIC CORPORATION, Seoul (KR)
PCT Filed Aug. 10, 2018, PCT No. PCT/KR2018/009151
§ 371(c)(1), (2) Date Feb. 10, 2020,
PCT Pub. No. WO2019/031902, PCT Pub. Date Feb. 14, 2019.
Claims priority of application No. 10-2017-0102316 (KR), filed on Aug. 11, 2017.
Prior Publication US 2020/0215040 A1, Jul. 9, 2020
Int. Cl. A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 9/0014 (2013.01); A61K 47/38 (2013.01)] 16 Claims
 
1. A pharmaceutical composition for topical use comprising:
a mixed solution of (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide represented by Formula (1)

OG Complex Work Unit Chemistry
dissolved in a solvent; and
an aqueous solution comprising a cellulosic polymer,
wherein the cellulosic polymer is Hypromellose,
wherein the aqueous solution comprising the cellulosic polymer has a viscosity of 2 to 10 mPa·s, a content of 1 to 5 wt. % of the total weight of the composition, and a weight ratio of 1:1 to 3:1 relative to the compound represented by Formula (1).